The median ratio of trastuzumab levels in the serum and cerebrospinal fluid (CSF) of Her2+ BC patients, for example, was found to be 420:1 [113], which could be improved to 76:1 upon co-treatment with RT. Here, ERBB2 is linked to breast cancer.